In addition to using the latest finding to guide the care provided to cancer survivors, the Survivorship Program team is dedicated to conducting research to learn more about the long-term and late effects of cancer treatment and to improve the quality of life for survivors.
Our researchers are involved in projects ranging from studying the long-term cardiovascular effects of cancer treatment, to examining the factors that determine emotional adjustment and quality of life.
Eligible survivors are invited to participate in research projects. As part of these efforts, all patients entering survivorship care are asked to complete a series of survivorship questionnaires about their physical, emotional, and medical experiences. This information is collected on an annual basis and helps us guide your survivorship care.
Researchers at the University of Iowa and Fred Hutch Cancer Center are developing a new web-based program to connect ovarian cancer patients and improve their quality of life. They are developing sessions on Stress Management, Maximizing Support from Friends and Family, Relaxation Techniques, Spirituality and Coping. Help improve this program by participating in a 10-week wellness and support group from your home and providing feedback on the website. Your involvement will take about 2 hours/week for 10 weeks by internet, plus training and activities to practice at home. For more information, call Ellen or Nita at the University of Iowa Department of Psychology (319) 335-0145. Email to Nitafirstname.lastname@example.org or Ellenemail@example.com or Dr. Bonnie McGregor at Fred Hutch firstname.lastname@example.org
Researchers at the Hutch are enrolling cancer survivors in a research program to help improve memory and thinking abilities in people experiencing cognitive problems after treatment. The program consists of a seven-week group workshop, with cognitive testing before and after the workshop. For more information, call (206) 667-7930.
Tamoxifen has been shown to reduce breast cancer risk by up to 50 percent in high-risk women. This study is evaluating whether a lower tamoxifen dose may also be effective, and with fewer side effects, in women who have received radiation to the chest wall, arm pit area, or whole body for cancer treatment. The study is enrolling eligible women who are at least 25 years old, received radiation treatment before age 40, and have remained free of disease for at least two years. This study is supported by a National Cancer Institute grant, information is available at www.seattlecca.org/clinical-trials/breastcancer-NCT01196936.cfm